QS Research · Michael Burry's Scion Capital analyst template · 2006
CLOROX CO /DE/ (CLX)
As of 2026-11-17 · 12/15 boxes filled from SEC filings and market data
Report price $106.70 (close 2026-11-17); latest close $104.73 (2026-11-20), -1.8% since the report; figures re-marked at the latest close
Conclusion: PASS
Conviction low · base case none · downside -26% · upside +10%
The market is not pricing a shrinking brand: the reverse DCF says today's $17.90B enterprise value needs +13.9% revenue growth a year for ten years, against -5.4% revenue growth in the fiscal year to 2026-06-30, so at 19.1x TTM earnings the price already assumes a return to growth the business does not show. The call is PASS because the two live cases sit close together and the anchor between them has failed. There is no base case: the company's own five-year median P/E of 37.56x, in a range of 18.3x to 131.9x against today's 19.1x, is flattered by a high historical base in weaker earnings years, so no comparable peer multiple sets one. The downside is -27.8% to $77.00 on -15.0% earnings at a compressed P/E of 16.23x (today 19.1x). The upside is +8.0% to $115.24 on +8% earnings at today's P/E of 19.1x. A reward-to-risk of 0.29 does not pay for a dividend the $453.0M of free cash flow fails to cover.
Key numbers
- Share price: $104.73
- Market cap: $12.69B
- Latest financial period: TTM to Sep 30, 2026
- Revenue (TTM): $7.20B
- EV / EBITDA (TTM): 13.4x
- P/E (TTM): 18.7x
- FCF yield: 3.6%
- Earnings-quality flags (TTM): none flagged
- EV / FCF (TTM): 39.0x
- Revenue growth (latest fiscal year): -5.4%
- ROIC (TTM): 15.1%
- WACC: 4.8%
- Economic profit spread: +10.4 pts
The 15 boxes
- ✓ 1. Long-form business notes
Clorox enters FY2027 as a roughly $6.7B-sales (FY2026) U.S.-weighted household and professional-products maker, 84% of FY2026 sales from U.S. markets, that has just swapped portfolio pieces: it exited vitamins/supplements, bought GOJO/Purell in April 2026 to add B2B health and hygiene, and bought out P&G's 20% of Glad when their venture expired on January 31, 2026. Sales fell from $7.34B in FY2021 to $6.72B in FY2026, while the TTM to 2026-09-30 is $7.20B because it carries roughly two quarters of the acquired business. The earnings engine is brand-share driven (over 80% of sales from No. 1 or No. 2 share brands) but sits on concentrated distribution: Walmart alone was 26% of FY2026 net sales and the top five customers about half. Costs and cash reflect a completed, over-budget digital build (~$580M versus the ~$500M first announced in August 2021) and a balance sheet with almost no common equity ($90.0M at June 30, 2026; -$39.0M at the TTM date).
- ✓ 2. Competitive advantage
CLX has a brand- and innovation-based competitive position, but the filing describes a highly competitive consumer-products market with private label, retailers, B2B channels, and some competitors that are larger and better resourced. Gross profit dollars have remained sizable ($2.54B-$3.21B across FY2021-FY2026; $3.02B TTM to 2026-09-30) while net income and cash flow have been uneven, and total equity is only $90M at FY2026 and -$39M TTM. The sources support a recognizable brand and R&D effort but not a quantified durable moat: no market-share, ROIC/ROE, or gross-margin ratio data are given.
- ✓ 3. 10-Q takeaways
Q1 FY2027 (quarter ended Sep 30, 2026) net sales rose 33% to $1.91B, with GOJO about 15 points and organic sales +18%; gross margin fell 130 bp to 40.4% on commodity and manufacturing/logistics costs. Diluted EPS was $1.39 vs $0.65 and adjusted EPS $1.55 vs $0.85; operating cash flow rose to $143M from $93M, with no share repurchases. FY2027 outlook keeps sales +13%-14% and adjusted EPS $5.70-$6.00 but points adjusted EPS toward the low end; risk discussion flags GOJO integration, tariffs and geopolitical conflict.
- ✓ 4. Corporate governance
Filled; members read this box.
- ✓ 5. Overview of the prior 3 years of 8-K filings
Filled; members read this box.
- ✓ 6. Other significant filings
Filled; members read this box.
- ✓ 7. Chronology of significant news and events
Filled; members read this box.
- ✓ 8. Comparables valuation interpretation
Filled; members read this box.
- ✓ 9. Insider trading interpretation
Filled; members read this box.
- ○ 10. Earnings-call notes
- ○ 11. Impression of the shareholder letter
- ○ 12. Scuttlebutt overview
- ✓ 13. Valuation and risk/reward summary
Filled; members read this box.
- ✓ 14. Current price suppression and potential catalysts
Filled; members read this box.
- ✓ 15. Conclusions
The call above.
Sign in with a QuantSignals Premium or Gold plan to read every box: each point linked to the SEC filing it came from, the bull and bear case, and the comparables. QS Research powers the signals behind FST, our autonomous trading agent.